Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2025 value amounting to $20.9 million.

  • Spero Therapeutics' Non-cash Items rose 208790000.0% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 208790000.0%. This contributed to the annual value of $1000.0 for FY2023, which is 9996.28% down from last year.
  • Per Spero Therapeutics' latest filing, its Non-cash Items stood at $20.9 million for Q3 2025, which was up 208790000.0% from $2.5 million recorded in Q2 2025.
  • Spero Therapeutics' Non-cash Items' 5-year high stood at $33.2 million during Q3 2021, with a 5-year trough of $1000.0 in Q4 2022.
  • In the last 5 years, Spero Therapeutics' Non-cash Items had a median value of $2.3 million in 2023 and averaged $5.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 9999.59% in 2022, then skyrocketed by 208790000.0% in 2025.
  • Quarter analysis of 5 years shows Spero Therapeutics' Non-cash Items stood at $24.3 million in 2021, then crashed by 100.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then skyrocketed by 2087900.0% to $20.9 million in 2025.
  • Its Non-cash Items stands at $20.9 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.5 million for Q1 2025.